Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 05/25 10:00:00 pm
64.56 USD   +0.39%
05/24 GILEAD SCIENCES : Value Trap?
05/19 GILEAD SCIENCES : considers producing Hep C drug in Egypt
05/19 GILEAD SCIENCES : American “Gilead Sciences” considers p..
News SummaryMost relevantAll newsSector newsTweets 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected] 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
05/24 GILEAD SCIENCES : Value Trap?
05/19 GILEAD SCIENCES : considers producing Hep C drug in Egypt
05/19 GILEAD SCIENCES : American “Gilead Sciences” considers producing new..
05/18 GILEAD SCIENCES, INC. (NASDAQ : GILD) Files An 8-K Submission of Matters to a Vo..
05/18 GILEAD SCIENCES : Submission of Matters to a Vote of Security Holders (form 8-K/..
05/12 GILEAD SCIENCES,INC. (NASDAQ : GILD) Files An 8-K Departure of Directors or Cert..
05/12 GILEAD SCIENCES INC : Change in Directors or Principal Officers, Submission of M..
05/11 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch Healthcare Con..
05/09 NATCO PHARMA : launches Hepatitis C drug Velpanat in India
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/25 GILEAD : Taking The Other Side Of The Bet
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 14 Stocks For 2017 And Beyond - May Update
05/24 How To Double Your Money On A 6% Up Move In Gilead Sciences
05/24 BBP : A Diversified Biotech ETF
Financials ($)
Sales 2017 24 515 M
EBIT 2017 15 036 M
Net income 2017 9 722 M
Debt 2017 4 528 M
Yield 2017 3,32%
P/E ratio 2017 8,63
P/E ratio 2018 9,53
EV / Sales 2017 3,61x
EV / Sales 2018 4,04x
Capitalization 84 036 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,6 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.19%84 101
AMGEN, INC.5.74%112 531
ACTELION LTD24.49%30 824
More Results